PROTHENA CORPORATION PLC - ORDINARY SHARES

Prothena to Participate in JMP Securities Hematology and Oncology Summit

29 Nov 2021 16:05:00 By Nasdaq GlobeNewswire

Prothena Reports Third Quarter 2021 Financial Results and Business Highlights

04 Nov 2021 16:05:02 By Nasdaq GlobeNewswire

Prothena to Report Third Quarter 2021 Financial Results on November 4th

28 Oct 2021 16:05:01 By Nasdaq GlobeNewswire

Prothena Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

01 Oct 2021 16:30:00 By Nasdaq GlobeNewswire

Prothena Announces Executive Appointments

01 Oct 2021 16:05:00 By Nasdaq GlobeNewswire

Prothena Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

03 Sep 2021 16:05:00 By Nasdaq GlobeNewswire

Prothena to Participate in Upcoming September Healthcare Conferences

01 Sep 2021 16:05:00 By Nasdaq GlobeNewswire

Prothena Reports Second Quarter 2021 Financial Results and Business Highlights

05 Aug 2021 16:05:02 By Nasdaq GlobeNewswire

Prothena to Report Second Quarter 2021 Financial Results on August 5th

29 Jul 2021 16:05:00 By Nasdaq GlobeNewswire

Prothena Presents New Data from Robust Alzheimer’s Portfolio at the Alzheimer’s Association International Conference 2021

26 Jul 2021 09:00:00 By Nasdaq GlobeNewswire

Prothena to Present Data from Two of its Alzheimer’s Disease Programs at the Alzheimer’s Association International Conference 2021

20 Jul 2021 16:05:00 By Nasdaq GlobeNewswire

Prothena and Novo Nordisk Announce Acquisition Agreement for Prothena’s ATTR Amyloidosis Programme

12 Jul 2021 07:00:00 By Nasdaq GlobeNewswire

Prothena Announces Bristol Myers Squibb Opt-in of Anti-Tau PRX005 as the First Program from Global Neuroscience Research and Development Collaboration

24 Jun 2021 08:30:00 By Nasdaq GlobeNewswire

Prothena to Participate in JMP Securities Life Sciences Conference on June 16

10 Jun 2021 14:18:16 By Nasdaq GlobeNewswire

Prothena Announces Appointment of Sanjiv Patel, MBBS, to its Board of Directors

20 May 2021 16:05:00 By Nasdaq GlobeNewswire

Prothena Reports First Quarter 2021 Financial Results and Provides Updated Financial Guidance and R&D Update

11 May 2021 16:05:01 By Nasdaq GlobeNewswire

Prothena Announces Achievement of $60 Million Milestone From Roche for First Patient Dosed in Phase 2b Study of Prasinezumab in Early Parkinson’s Disease

10 May 2021 16:05:01 By Nasdaq GlobeNewswire

Prothena Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

07 May 2021 16:05:00 By Nasdaq GlobeNewswire

Prothena to Report First Quarter 2021 Financial Results on May 11th

04 May 2021 16:05:00 By Nasdaq GlobeNewswire

Prothena Presents Phase 1 Study Results of PRX004 in Oral Presentation at AAN 2021

18 Apr 2021 15:05:00 By Nasdaq GlobeNewswire